Stock comparison
Bio-Rad Laboratories
BIO$8.74BHealthcare Market cap, Sector
Pro Medicus Limited
PME.AX$16.79BHealthcare Market cap, Sector
Overall winner
Pro Medicus Limited
BIO 07 PME.AX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
Fit scores by strategy
BIO0wins
7winsPME.AX
41F
B78
46D
A90
28F
A98
8F
A100
40F
B84
32F
A91
24F
A96
Side-by-side metrics
| Metric | BIO | PME.AX |
|---|---|---|
| Market cap | $8.74B | $16.79B Winner |
| P/E (TTM) | Winner: 39.5x | 147.6x |
| EV/EBIT | Winner: 28.0x | 106.8x |
| ROIC (TTM) | 1.95% | 42.56% Winner |
| Gross margin | 51.87% | 99.85% Winner |
| Net margin | 6.52% | 54.12% Winner |
| Revenue CAGR 5y | -3.04% | 31.61% Winner |
| EPS CAGR 5y | -33.51% | 37.34% Winner |
| Debt / Equity | 0.2x | 0.0x Winner |
| Dividend yield | 0.0% | - |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
BIO leads on
- EV/EBIT28.0xvs 106.8x+74%
- P/E (TTM)39.5xvs 147.6x+73%
PME.AX leads on
- EPS CAGR 5y37.34%vs -33.51%+190%
- Revenue CAGR 5y31.61%vs -3.04%+110%
- Debt / Equity0.0xvs 0.2x+96%
- ROIC (TTM)42.56%vs 1.95%+95%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.